The live attenuated yellow fever virus vaccine (YFV-17D) that confers life-long protective immunity is one of the most effective vaccines ever developed. The knowledge gained from understanding the molecular mechanisms of how this vaccine works will provide the platform to rationally develop new vaccines against emerging diseases including dengue virus that is now a major global epidemic. Project 1 (Ahmed/Wilson) will focus on immune memory, using a novel in vivo labeling technique in humans will measure the homeostasis and longevity of YFV-specific T cells, track the migration of YFV-17D-induced T cells to mucosal sites, and examine the relationship between CD4 T follicular helper cells (TFH) response and the type of antibody produced after both YFV-17D vaccination and dengue infection. Project 2 (Pulendran/Rice) will determine the molecular mechanisms by which the yellow fever vaccine strain YFV-17D and the pathogenic Asibi strain, as well as dengue virus, stimulate innate immunity to program adaptive immune responses. They will also examine a new paradigm of how the immune system can sense viruses by detecting stress signals in the environment, and modulate adaptive immunity. Project 3 (Goronzy) will examine signaling checkpoints that are important for CD4 T cell memory differentiation and that are compromised in the elderly and relate the epigenetic changes to these critical signaling checkpoints, in particular the AMPK and SIRT1 signaling pathways. A great limitation in human vaccine studies is the low frequency of antigen-specific cells and their inherent heterogeneity, which is amplified in the elderly who respond poorly to vaccination. The goal of the Technology Development Project (TDP) (Haining/Greenleaf) is to develop and apply sensitive assays to measure the transcriptional profiles and epigenetic state in rare cell populations or even single cells. This technology will be applied to each of the Research Projects. The human samples for the Research Projects and TDP will be provided by Core C (Mulligan/Yu/Chokephaibulkit) which is located at two sites: 1) The Emory Hope Clinic where volunteers will be enrolled into the YFV-17D studies. 2) Dengue Clinical Unit, at Siriraj Hospital, Bangkok, Thailand where dengue infected patients will be enrolled.

Public Health Relevance

Vaccines are one of the most cost-effective weapons to prevent infectious diseases and protect public health. A better understanding of the fundamental immunological mechanisms that constitute one of world's most effective vaccines (YFV-17D) would guide the rational design of future vaccines, including for the increasing elderly population. Dengue infection is a global epidemic, understanding the innate and adaptive immune responses to dengue infection would lead to the development of a much needed vaccine.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19AI057266-11
Application #
8709050
Study Section
Special Emphasis Panel (ZAI1-LAR-I (J1))
Program Officer
Quill, Helen R
Project Start
2003-09-01
Project End
2019-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
11
Fiscal Year
2014
Total Cost
$2,884,146
Indirect Cost
$714,275
Name
Emory University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Fang, Fengqin; Yu, Mingcan; Cavanagh, Mary M et al. (2016) Expression of CD39 on Activated T Cells Impairs their Survival in Older Individuals. Cell Rep 14:1218-31
Ravindran, Rajesh; Loebbermann, Jens; Nakaya, Helder I et al. (2016) The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation. Nature 531:523-7
Chandele, Anmol; Sewatanon, Jaturong; Gunisetty, Sivaram et al. (2016) Characterization of Human CD8 T Cell Responses in Dengue Virus-Infected Patients from India. J Virol 90:11259-11278
Neu, Karlynn E; Henry Dunand, Carole J; Wilson, Patrick C (2016) Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Curr Opin Immunol 42:48-55
DiLillo, David J; Palese, Peter; Wilson, Patrick C et al. (2016) Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest 126:605-10
Henry Dunand, Carole J; Leon, Paul E; Huang, Min et al. (2016) Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host Microbe 19:800-13
Qi, Qian; Cavanagh, Mary M; Le Saux, Sabine et al. (2016) Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination. Sci Transl Med 8:332ra46
Ho, Irvin Y; Bunker, Jeffrey J; Erickson, Steven A et al. (2016) Refined protocol for generating monoclonal antibodies from single human and murine B cells. J Immunol Methods 438:67-70
Nakaya, Helder I; Clutterbuck, Elizabeth; Kazmin, Dmitri et al. (2016) Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proc Natl Acad Sci U S A 113:1853-8
Burke, Rachel M; Suchdev, Parminder S; Rebolledo, Paulina A et al. (2016) Predictors of Inflammation in a Cohort of Bolivian Infants and Toddlers. Am J Trop Med Hyg 95:954-963

Showing the most recent 10 out of 202 publications